Of the 350 million people who suffer from Major Depressive Disorder (MDD) worldwide, many are not adequately treating their depression symptoms with their current SSRI treatment. A major pharma company designed a multinational study for the large subset of patients who are symptomatic despite their treatment. On-time study enrollment was critical for the success of the Sponsor’s high profile investigational drug – one that could potentially provide a large population of patients with the treatment they need for chronic, residual symptoms.
The magnitude of the Sponsor’s study, and the nature of MDD and its effect on patients, set the backdrop for BBK’s recruitment efforts. Composed of four protocols and spanning 24 countries, the study required more than 6,700 patients screened over the course of two and a half years to meet enrollment goals. To achieve this, BBK was tasked with establishing operational consistency on a global scale while ensuring dynamic strategic outreach adaptation on a country and site level.
To reach the study enrollment goal, BBK needed to:
Through our experience in managing key stakeholder relationships among top pharma companies and healthcare organizations, and developing data-driven, adaptive engagement strategies, BBK positioned the study to meet its screening and enrollment goals.
The expedient, informed development and placement of media and advertising was essential to the success of this study. Our creative assets were carefully crafted so they could be easily adapted and deployed to best service our diverse site localities. We generated meaningful and extensive research through our deep analysis of the cultural landscapes across 24 countries, and with this research, we adapted our outreach strategies as a whole to resonate with each country’s MDD population. Our ongoing analysis of strategic and tactical performance enabled us to define and implement the strongest and most cost effective strategies across all channels. BBK’s mixed-tactic marketing campaign generated 25,719 pre-qualified referrals for the study globally. Our high-volume referral generation and robust advertising support resulted in a 50 percent increase in global screening rates, saving the study a cumulative 60 days.